Product Reviews
Categories
- Alternative Medicine
- Cancer
- Acute Promyelocytic Leukemia
- Anal Cancer
- Bladder Cancer
- Breast cancer
- Colorectal cancer
- Endometrial Cancer
- Esophageal Cancer
- Gallbladder cancer
- Gastric Cancer
- Glioblastma
- Head and Neck Cancer
- Liver Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Nasopharyngeal Cancer
- Non-Hodgkin's Disease
- Ovarian Cancer
- Pancreatic Cancer
- Prostate cancer
- Renal Cancer
- Thyroid Cancer
- Cardiovascular disease
- Central Nervous System
- Constipation
- Diabetes
- Fatty Liver
- Irritable Bowel Syndrome
- Longevity
- Motherhood
- Obesity
- Others
- Psoriasis
- Respiratory Disease
- Rheumatoid Arthritis
Archives
Tag Archives: eribulin
FDA Approves Halaven for Late-Stage Breast Cancer
Good news for patients with late stage metastatic breast cancer. The US Food and Drug Administration (FDA) approved eribulin mesylate injection (Halaven; Eisai, Inc) for the treatment of metastatic breast cancer in patients who have received at least 2 prior … Continue reading →
Posted in Breast cancer, Cancer
|
Tagged anthracycline, Bristol-Myers Squibb, capecitabine, chemotherapy, Eisai, eribulin, Halaven, ixabepilone, Ixempra, Metastatic breast cancer, paclitaxel, resistant, Roche, Survival, taxane, Xeloda
|
Comments Off on FDA Approves Halaven for Late-Stage Breast Cancer
New Hope for Heavily Pretreated Metastatic Breast Cancer Patients
A new chemotherapy agent, eribulin (developed by Eisai), was shown to improve significant survival benefit in heavily pretreated breast cancer, according to the EMBRACE study presented at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting. The new drug … Continue reading →
Posted in Breast cancer, Cancer
|
Tagged anthracyclines, capecitabine, EMBRACE, eribulin, gemcitabine, halichondrins, Metastatic breast cancer, Survival, taxane, vinorelbine
|
Comments Off on New Hope for Heavily Pretreated Metastatic Breast Cancer Patients
